Phoenix, Arizona (PRWEB) October 30, 2013
Botanisol™, a Glendale-based high-tech firm, has applied for a $250,000 grant from Chase as part of a newly launched program, Mission Main Street(SM) Grants. If selected, the funds will go to create high paying research associate jobs and complete pre-clinical development of a powerful new anti-inflammatory therapeutic. Consumers, friends, family and fans can show support by voting for Botanisol™ at:
Botanisol occupies a unique position in biomedical research and is a leader in the development of new bioactive compounds from botanical and natural sources. Through collaboration with the University of Arizona, the company is currently developing an anti-inflammatory discovery from NIH supported research. The product is a potential alternative to NSAIDs (non-steroid anti-inflammatory drugs) and natural supplements used to treat pain due to inflammation. The Botanisol™ product reduces inflammation in a manner different from NSAIDs. NSAIDs are known to cause serious adverse effects in patients, resulting in 100K hospitalizations, 16.5K deaths and more than $2 billion in cost to the US healthcare system annually.